Promotie onderzoek

The aim of this project is to provide insight in the use of biologicals, including biosimilars, in clinical practice and add to the safe and effective use of these agents. We also provide guidance on the implementation of biosimilars in clinical practice from the perspective of different stakeholders including prescribers, pharmacists and patients.

New medicines are evaluated by registration authorities in order to assess their benefit-risk-balance. However, not every new medicine has to have an added therapeutic value compared to already available medicines. The real clinical relevance of new medicine is therefore sometimes unclear. In this research project, we want to investigate the views of healthcare professionals (HCPs) on clinical relevance of new medicines in primary care. We will discuss healthcare professionals’ views on clinical relevance of new COPD and T2DM medicines and also describe the reasons for prescribing new medicines, which is often not in line with guideline recommendations. Finally, we want to investigate how healthcare professionals assess the clinical relevance of medicines that obtained market access in the last years, and to investigate which pharmaceutical gaps (in other words: which diseases cannot be properly treated and would demand new therapies) HCPs identify in their daily practice. 

1. Stress-relieving: 3D printing personalized cortisol for patients with adrenal insufficiency
2. A novel delayed release hydrocortison formulation for patients with adrenal insufficiency
3. Feasibility study of 10 mg 3D printed systained release hydrocortisone 
4. Feasibility study of 3D printed delayed release hydrocortisone 
5. RCT of novel 3D printed hydrocortisone vs standard of care in adrenal insufficiency 

Het doel van dit onderzoek is het onderzoeken welke immunologische en immunofarmacologische diagnostiek kan worden gebruikt om immunotherapie van longkanker te verbeteren.

Onderzoeken van risico factoren die de microbiologische kwaliteit van de aseptische bereiding bepalen en welke beheersmaatregelen getroffen kunnen worden..

Een geneesmiddel wat al tientallen jaren wordt gemaakt willen we registreren. Welke onderzoeken moeten we nog uitvoeren, welke onderzoeken zijn overbodig als het al zolang klinisch wordt gebruikt. En wat kunnen we hieruit leren voor apotheekbereidingen in het algemeen en voor apotheekbereidingen die we beter willen beschermen door ze te registreren?